1. Home
  2. TY vs DNTH Comparison

TY vs DNTH Comparison

Compare TY & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tri Continental Corporation

TY

Tri Continental Corporation

HOLD

Current Price

$33.36

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Logo Dianthus Therapeutics Inc.

DNTH

Dianthus Therapeutics Inc.

HOLD

Current Price

$50.34

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TY
DNTH
Founded
1929
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.9B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TY
DNTH
Price
$33.36
$50.34
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$68.88
AVG Volume (30 Days)
43.0K
765.5K
Earning Date
01-01-0001
03-10-2026
Dividend Yield
3.36%
N/A
EPS Growth
N/A
N/A
EPS
4.78
N/A
Revenue
N/A
$3,078,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.38
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.16
$13.37
52 Week High
$30.73
$54.00

Technical Indicators

Market Signals
Indicator
TY
DNTH
Relative Strength Index (RSI) 54.76 66.86
Support Level $32.53 $50.00
Resistance Level $33.54 $54.00
Average True Range (ATR) 0.28 3.08
MACD 0.07 1.10
Stochastic Oscillator 81.68 81.05

Price Performance

Historical Comparison
TY
DNTH

About TY Tri Continental Corporation

Tri-Continental Corp is a United States-based closed-end management investment company. It invests to produce future growth of both capital and income while providing reasonable current income. The fund is divided into two equal segments namely, the equity segment uses quantitative models to select individual stocks whereas the Flexible capital income segment invests across a company's investable capital structure, including stocks, bonds, and convertible securities. The Fund invests in a range of sectors, which include consumer discretionary, consumer staples, energy, financials, healthcare, industrials, information technology, industrials, materials, real estate, telecommunication services, utilities, aerospace and defense, banking, chemicals, and others.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Share on Social Networks: